The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial (Q85018672)
Jump to navigation
Jump to search
scientific article published on 17 November 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial |
scientific article published on 17 November 2011 |
Statements
The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial (English)
D P Modest
A Jung
N Moosmann
R P Laubender
C Giessen
C Schulz
M Haas
J Neumann
S Boeck
T Kirchner
17 November 2011